We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Identified That Promotes Childhood Cancers

By LabMedica International staff writers
Posted on 03 Sep 2014
A gene has been identified that contributes to the development of several childhood cancers and this could lead to new strategies for targeting certain childhood cancers at a molecular level. More...


Ribonucleic acid (RNA)-binding proteins that influence stem cell maintenance, metabolism, and oncogenes, and in poorly differentiated, aggressive cancers are often overexpressed, have their role in tumor initiation or maintenance not definitively addressed.

Scientists at The University of Texas Southwestern Medical Center (Dallas, TX, USA) used a murine model to study the RNA-binding proteins Lin28a/b. The Lin-28 Homolog B gene (LIN28B) overexpression is sufficient to initiate hepatoblastoma and hepatocellular carcinoma in murine models. The team also detected LIN28B overexpression in V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC)-driven hepatoblastomas, and liver-specific deletion of Lin28a/b reduced tumor burden, extended latency, and prolonged survival.

Insulin-like growth factor 2 mRNA binding protein (Igf2bp) proteins are upregulated, and the gene Igf2bp3 is required in the context of LIN28B overexpression to promote growth. Therefore, the multiple murine models demonstrate that LIN28B is both sufficient to initiate liver cancer and necessary for its maintenance. Both intravenous small interfering RNA (siRNA) against LIN28B and conditional LIN28B deletion reduced tumor burden and prolonged survival.

Hao Zhu, MD, a professor of Pediatrics and Internal Medicine and senior author of the study said. “We and others have found that LIN28B—a gene that is normally turned on in fetal but not adult tissues—is expressed in several childhood cancers, including neuroblastoma, Wilms' tumor, and hepatoblastoma, a type of cancer that accounts for nearly 80% of all liver tumors in children. In our study, we found that overproduction of LIN28B specifically causes hepatoblastoma, while blocking LIN28B impairs the cancer's growth. This opens up the possibility that pediatric liver cancer patients could one day be treated without resorting to chemotherapy.” The study was published on August 11, 2014, in the journal Cancer Cell.

Related Links:

The University of Texas Southwestern Medical Center 



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.